Since the promising results of McKneally et al,1-3 there has been renewed interest in immunotherapy as an adjunct to surgery in patients with lung cancer. Their approach to immunotherapy with intrapleural administration of BCG after operation was based on the clinical observation of improved survival in patients developing empyema after resection.4 5 In contrast to intradermal and subdermal BCG,6 7 intrapleural BCG comes into close contact with the tumour cells possibly left after operation, which might favour optimal immune stimulation. 8 We initiated a study primarily designed to determine the safety of intrapleural administration of different dosages of BCG after surgery. This report presents the survival data of patients receiving postoperative BCG The vaccine was grown as a homogeneous culture using a seed lot derived from BCG Pasteur (Strain 1173). Isoniazid 300 mg/day was started three weeks after the BCG and continued for three months.
All patients were followed up by their chest physicians. No The median time of follow-up in the study group and control group was 10 and 28 months respectively. The survival curves of the study group and the control group did not differ significantly (log rank test x2 = 1 11, p > 0-1, fig 1) . Furthermore, the shape of the survival curves did not differ materially in the two groups, and when comparing the diseasefree intervals there were no significant differences between the two groups.
Removal of patients with anaplastic carcinoma and unknown histology did not influence these results. Subgroups fig 2) . This effect was mainly caused by the earlier appearance of local recurrences and to a lesser extent by the appearance of distant metastases in the BCG-treated patients. As for survival, there were six deaths from carcinoma among the 28 BCG receivers and five among the 49 controls at 24 months follow-up (0-05 < p < 0-10, median time of follow-up 15 and 32 months respectively).
When comparing the 36 BCG-treated patients with epidermoid carcinoma stage I plus stage II with the equivalent subgroup of the controls (n = 67) comparable results were obtained: a statistically significantly shorter disease-free interval in the BCG receivers was seen (p < 0-05), mainly because of the earlier appearance of local recurrences, and a trend towards a shorter survival (0 05 < p < 0O10).
After removal of patients with epidermoid carcinoma stage I no differences were found between the BCG receivers and the controls. Other subdivisions of the BCG-treated patients resulted in groups too small for analysis. The time of follow-up was too short to evaluate a dose-dependent effect of the BCG.
Discussion
The study group and the control group turned out to be sufficiently alike for it to be likely that differences in survival and disease-free interval between the two groups are caused by the BCG treatment. Since a patient had to be in a relatively good condition to be selected for BCG We have observed serious side-effects caused by the intrapleural administration of BCG.19The strong specific inflammatory reaction apparently evoked failed to produce the desired non-specific immunostimulative action.
We conclude that postoperative intrapleural BCG in lung cancer, as used in this study, has no beneficial effect on survival or on disease-free interval. Evidence to the contrary has been presented hinting to a possible enhanced tumour growth in patients with stage I epidermoid carcinoma. 
